Mutagenesis by an antisense oligonucleotide and its degradation product. by Reshat, R et al.
 1 
 
Running title: Mutation by an antisense oligonucleotide 
 
Mutagenesis by an antisense oligonucleotide and its degradation product  
 
Reshat Reshat
§
, Catherine C. Priestley
¶
, and Nigel J. Gooderham
§
*  
 
§
Biomolecular Medicine, Imperial College, London, SW7 2AZ, UK;  
¶
Genetic Toxicology, AstraZeneca, Macclesfield, Cheshire, SK10 4TG, UK. 
 
RR: r.reshat08@imperial.ac.uk  
CCP: catherine.priestley@astrazeneca.com  
NJG: n.gooderham@imperial.ac.uk  
 
*To whom correspondence should be addressed (n.gooderham@imperial.ac.uk) 
 
Corresponding Author: 
Professor Nigel J Gooderham 
Biomolecular Medicine 
Imperial College London 
Sir Alexander Fleming building 
London, SW7 2AZ 
Email: n.gooderham@imperial.ac.uk 
Tel: 0207 594 3188 
 
 
 
Page 1 of 38 Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 2 
 
Abstract 
The European Medicines Agency (EMA) has expressed concern regarding (i) the potential 
for antisense oligonucleotide (ASO) therapeutics to induce sequence specific mutation at 
genomic DNA and (ii) the capability of ASO degradation products (nucleotide analogues) to 
incorporate into newly synthesised genomic DNA via DNA polymerase and cause mutation if 
base-pairing occurs with reduced fidelity. Treating human lymphoblastoid cells with a 
biologically active antisense molecule induced sequence specific mutation within genomic 
DNA over four fold, in a system where RAD51 protein expression was induced. This finding 
has implications for ASO therapeutics with individuals with an induced DNA damage 
response, such as cancer patients.  Furthermore, a phosphorothioate nucleotide analogue 
potently induced mutation at genomic DNA two orders of magnitude above control. This 
study shows that a biologically active ASO molecule can induce heritable sequence 
alterations, and if degraded, its respective analogue may incorporate into genomic DNA with 
mutagenic consequences. 
 
 
Key words: antisense oligonucleotides, targeted nucleotide exchange, mutation, nucleotide 
analogues, genomic DNA. 
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Introduction 
The potential for ASO to modulate protein expression by translational repression or RNase H 
mediated degradation has application as a powerful therapeutic tool (Denli and Hannon, 
2003, Zamore, 2001). However, recent studies demonstrating the potential for 
oligonucleotides to induce site directed mutation within reporter genes has caused concern 
regarding the potential for oligonucleotide based pharmaceuticals to induce heritable 
sequence alterations (European Medicines Agency, 2004).  
In a process known as targeted nucleotide exchange (TNE), oligonucleotides have 
been reported to induce mutation mainly within engineered reporter constructs (Bonner and 
Kmiec, 2009, Dekker et al., 2003, Olsen et al., 2009). Oligonucleotides, typically over 45 
nucleotides in length, are designed to bind complementary to the non-transcribed (sense) 
strand within duplex DNA. Oligonucleotides with a single mismatched base, relative to its 
homologous sequence, are capable of directing mutation to the site of the mismatch. For 
example, a mutant GFP construct carrying a single inactivating point mutation was reported 
to be corrected, to the wild-type sequence restoring fluorescence, using a 74-mer 
oligonucleotide with correction frequencies in the order of 2% (Bonner and Kmiec, 2009). 
 Furthermore, the potential for nucleotide analogues, released as oligonucleotide 
degradation products, to enter intracellular nucleotide pools has been questioned by the EMA 
but genotoxicity was deemed unlikely (European Medicines Agency, 2004); if base pairing 
with the nucleotide analogue occurred with reduced fidelity, mutation might be expected. The 
genotoxicity of antiviral nucleoside analogues has been well established (Wutzler and Thust, 
2001), but these analogues are not used in ASO construction. Significantly, perturbation of 
endogenous nucleotide pools even by excess canonical nucleosides or nucleotides can also 
have a mutagenic consequence (Mattano et al., 1990, Phear et al., 1987). 
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 This study has addressed these concerns by examining the genotoxicity of an ASO 
entity and its putative degradation products.  
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Materials and methods 
Oligonucleotides. All oligonucleotides were DNA based and obtained from Sigma Genosys. 
Oligonucleotides were chemically modified to contain four terminal phosphorothioate 
linkages and reverse phase purified. Oligonucleotide sequences are as follows: AD3-hprtPM 
5’-A*C*A*G*TCATAGGAATGGATA*T*A*T*C-3’ and control 5’-A*C*C*T*TGAT 
GGCAAATAGGT*A*A*T*A-3’. The * indicates the position of the phosphorothioate 
linkage. 
 
Cell culture. Human lymphoblastoid TK6 cells were obtained from ATCC. TK6 cells were 
cultured in RPMI 1640 media supplemented with 10%v/v heat inactivated horse serum, L-
glutamine (2 mM), penicillin (100 units/ml) and streptomycin (100 µg/ml). All cell culture 
reagents were obtained from Invitrogen, unless otherwise stated.  
 
Induction of RAD51 protein expression in TK6 cells using methyl methanesulfonate 
(MMS). Exponentially growing TK6 cells were treated with MMS (0 µg/ml, 0.1 µg/ml, 0.2 
µg/ml or 0.5 µg/ml) for 24 h to induce RAD51 protein expression. Following treatment, TK6 
cells were washed in culture media and maintained in exponential growth for up to 72 h. 
Aliquots of TK6 cells were removed at 2 h, 4 h, 8 h, 24 h, 48 h and 72 h following treatment 
and washed in ice cold PBS for protein extraction and subsequent immunoblot analysis to 
determine RAD51 protein expression. The optimum concentration of MMS was used to pre-
treat TK6 cells the day before treatment with oligonucleotide.  
 
Total protein extraction. Total cell protein content was extracted by suspending cell pellets 
in freshly made lysis buffer (1 µl Halt protease inhibitor + 99 µl of 150 mM NaCl, 0.1%v/v 
igepal, 1 mM Tris (pH 7.4) and 1 mM EDTA) on ice for 20 mins. Samples were then 
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centrifuged at 10,000x g for 10 mins at 4 °C. Supernatants were collected into fresh 
eppendorf tubes and stored at -20 °C. Protein content in samples was determined using the 
bicinchoninic acid (BCA) assay according to manufacturer’s protocol (Thermo Scientific). 
 
Immunoblot. Protein expression was determined by immunoblot. In brief, for ADAMTS3 
and RAD51 protein expression, total protein (20 µg) was loaded per well. Samples were 
electrophoresed through 10% SDS-polyacrylamide gel and transferred on to a PVDF 
membrane. Membranes were stained with primary antibody overnight; for RAD51, 1:2000 
mouse anti-human RAD51 antibody; for ADAMTS3, 1:2000 rabbit anti-human ADAMTS3 
antibody. Following primary antibody staining and several wash steps, blots were stained 
with HRP-conjugated secondary antibody and visualised. GAPDH protein expression was 
employed as a loading control using primary rabbit anti-human GAPDH antibody (1:1000). 
Protein expression was determined using densitometry and normalised to GAPDH loading 
control.  
 
HPRT and TK forward mutation assay.  
a. Treating TK6 cells with oligonucleotide. For treatment of TK6 cells with 
oligonucleotide, the desired concentration of oligonucleotide was mixed with siPORT NeoFX 
(Ambion) and allowed to stand to allow complex formation. Meanwhile, TK6 cells were 
counted and 3x10
6
 cells were aliquoted per treatment and mixed with the 
oligonucleotide/siPORT complex. Treatments were in three independent cultures. 
Transfection was allowed to occur for 4 h at 37 °C, 5% CO2. TK6 cells were then washed and 
suspended for culturing overnight. As a positive genotoxic control, TK6 cells were treated 
with ethyl methanesulphonate (EMS; 5 µg/ml). To measure the spontaneous mutant 
frequency at each locus, oligonucleotide transfection mixtures were replaced with culture 
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media (Background). Following treatment of TK6 cells with oligonucleotide, cells were 
sampled (24 h, 48 h and 72 h) for protein extraction, to determine ADAMTS3 protein 
expression, by immunoblot, as a marker of AD3-hprtPM antisense activity. 
 
b. Treating TK6 cells with nucleotides. For treatment of TK6 cells with nucleotide, 4x10
6
 
TK6 cells were aliquoted per 75 cm
2
 flask in a 5 ml volume. Serial dilutions of nucleotides 
were dissolved in cell culture media to a final 2x concentration. Cells (5 ml) were mixed with 
2x nucleotide (5 ml). As a negative control, culture media (5 ml) replaced the nucleotide. 
EMS (5 µg/ml) was used as a positive control. Cells were exposed to test compounds for 24 
h. Following treatment, cells were pelleted at 200x g for 5 mins and washed with culture 
media. 
 
c. Determining cytotoxicity and the TK and HPRT mutant frequency. Following 
treatment of TK6 cells with oligonucleotide or nucleotide, cells were counted daily for three 
days to determine the relative suspension growth (RSG; a measure of cell death and 
proliferative ability following treatment (Clive et al., 1995, Clements, 2000). On the third 
day, TK6 cells were plated at 1.6 cells per well in 96 well plates to determine cloning 
efficiency and 20,000 cells per well in trifluorothymidine to determine the TK mutant 
frequency. This cloning efficiency was used to correct the RSG to give the relative total 
growth (RTG) as a measure of cytotoxicity following treatment. The remaining cells were 
maintained for a further four days phenotypic expression. Following this, the HPRT mutant 
frequency was then determined by seeding 20,000 cells per well in 96 well plates in 6-
thioguanine and cloning efficiency determined by seeding 1.6 cells per well in the absence of 
6-TG. Plates were incubated for 14 days minimum at 37 °C, 5%CO2 and then colonies were 
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scored. Mutant clones were individually isolated and expanded in 6-well plates for 7-10 days 
for genomic DNA extraction and PCR amplification. 
 
Genomic DNA extraction. Genomic DNA was extracted from TK6 cells using the QIAamp 
DNA Blood mini kit (Qiagen, Crawley) according to manufacturer’s instructions. In brief, 
pelleted TK6 cells were suspended in PBS containing with proteinase K and lysis buffer AL. 
Samples were mixed by pulse vortexing and incubated at 56 °C for 10 mins. Lysates were 
mixed with ethanol and added to a spin column followed by centrifugation. Columns were 
washed with wash buffer AW1 and then AW2. DNA was eluted out of the spin column using 
DNase/RNase free water. DNA was quantified using the NanoDrop ND1000 
spectrophotometer.  
 
Polymerase chain reaction and DNA sequencing. PCR reactions were performed to 
amplify a  one Kb region of exon 3 in the HPRT locus which enclosed the AD3-hprtPM 
target sequence. A typical reaction was in a 50 µl reaction volume containing genomic DNA 
(300 ng to 1 µg) from isolated HPRT mutant clones, 200 nM of each forward (5’-
AGGGCAAAGGATGTGTTACG-3’) and reverse (5’-AGTGGTTTCTGGTGCGACTT-3’) 
primer, dNTPs (200 µM),  Tfi polymerase (5 units) and 1x Tfi PCR buffer supplemented with 
MgCl2 (1.5 mM). Amplification was performed using a Peltier thermal cycler as follows: 
initial denaturation step at 94 °C for 4 mins, followed by 35 cycles of denaturing at 94 °C for 
30 secs, annealing at 58 °C for 30 secs and polymerisation at 72 °C for 1 min. The final 
polymerisation step was extended to 7 mins. Samples were then stored at 4 °C until time of 
analysis. Aliquots of PCR products were resolved by electrophoresis through a 1.2% agarose 
gel containing ethidium bromide (0.5 µg/ml) and visualised under UV. PCR products were 
extracted and purified for DNA sequencing using the PureLink Quick gel extraction kit 
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(Invitrogen, Paisley), according to manufacturer’s protocol. Purified PCR products were 
diluted to 10 ng/µl and sent for sequencing by Gene Service ltd (Source Bioscience).  
 
Mbo I restriction enzyme digestion of PCR products. PCR products from HPRT mutant 
clones were subject to Mbo I restriction enzyme digestion to inform the integrity of the 5’-
GATC-3’ recognition sequence. PCR products containing wild-type sequence results in 
cleavage into two fragments; 474 bp and 544 bp. Mutation within the 5’-GATC-3’ sequence 
results in resistance to Mbo I restriction enzyme digestion. Typically, PCR products were 
restriction enzyme digested with Mbo I restriction enzyme (4 units) for 1 h at 37 °C. Digested 
PCR products were resolved on 1.2%w/v agarose gels containing ethidium bromide (0.5 
µg/ml) and visualised under UV.   
 
Primer extension assay. This method was adapted from Lacenere and co-workers (Lacenere 
et al., 2006). Primed template, with an overhang of 5 thymidine nucleotides, was made by 
annealing template strand (5’-TTTTTCCCACAAACCAAAAGCCCAGACACA-3’) with the 
complementary primer strand (5’-6FAM-TGTGTCTGGGCTTTTGGTTTGTGGG-3’) which 
is labelled with a 5’ fluorophore in annealing buffer (75 mM Tris pH 7.2 and 75 mM NaCl). 
A typical reaction mixture contained primed template (25 nM),  Tfi DNA polymerase (0.6 
units), MgCl2 (3.5 mM), 1x Tfi PCR buffer and nucleotide in a 20 µl volume. As a negative 
control in experiments, nucleotide was omitted.  Reactions were allowed to incubate for the 
required length of time at 72 °C to permit extension of the primed duplex. Following this, 
EDTA (5 µl of 1M) was added to stop the reaction. Primed template in the reaction mixture 
was then denatured by adding 25 µl of UREA gel loading buffer (1.5 M sucrose, 7 M UREA, 
10 mM EDTA, 0.1% bromophenol blue) and heated at 95 °C for 5 mins with immediate 
transfer to ice slurry. Samples were then subject to electrophoresis through a 14% 8 M 
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UREA-polyacrylamide gel at 120 V for 3 h. 6FAM labelled primer strand was visualised at 
490 nm/530 nm.  
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Results 
Design of an ASO.  
In the first instance, an ASO was designed to bind complimentary to the mRNA of the 
ADAMTS3 gene as well as contain sequence homology to the Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) locus except a single mismatched base (AD3-hprtPM; 
Fig. 1). It was proposed that AD3-hprtPM would act as an antisense molecule in modulating 
ADAMTS3 protein expression whilst the HPRT locus served as a genomic reporter of off-
target genotoxicity, which could be quantified using the established HPRT forward mutation 
assay. The integrity of the genomic Thymidine kinase (TK) locus served as a reporter of 
sequence independent genotoxicity following oligonucleotide treatments. 
As a negative control, an oligonucleotide was employed with the same base 
composition as AD3-hprtPM but in a random order (control; Fig. 1). Oligonucleotides were 
chemically modified to contain 4 terminal phosphorothioate linkages at either end to increase 
nuclease resistance (Kenner et al., 2002). 
 
Antisense activity of AD3-hprtPM. 
Human lymphoblastoid TK6 cells were treated with AD3-hprtPM and control 
oligonucleotides up to 10µM to inform antisense activity. Treated cells were sampled at 24h, 
48h and 72h to determine ADAMTS3 protein expression (Fig. 2, A-C). Gels were quantitated 
using densitometry and ADAMTS3 protein expression was normalised to control 
oligonucleotide treatment at the respective dose and time (Fig. 2D); AD3-hprtPM induced a 
dose and time dependent knockdown of ADAMTS3 protein expression by 20-30% with 5µM 
and 10µM treatment by 48h and was further reduced by 45-70% by 72h. 
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Sequence specific mutation at genomic DNA by AD3-hprtPM. 
To quantify off-target genotoxicity caused by the presence of AD3-hprtPM, the HPRT 
forward mutation assay was employed. Previous studies have proposed the involvement of 
homologous recombination (HR) repair in the process of TNE (Radecke et al., 2006, 
Morozov and Wawrousek, 2008). To investigate this, a dose range of the genotoxin methyl 
methanesulfonate (MMS) was used to induce RAD51 protein expression as a marker of HR 
repair activity (Gupta et al., 1997, Saleh-Gohari et al., 2005, Sung and Robberson, 1995). 
MMS treatment is  likely to induce repair pathways other than HR repair but it is HR repair 
that is most likely to facilitate oligonucleotide mediated mutation. Human TK6 cells were 
treated for 24h with MMS up to 0.5µg/ml and aliquots of cells were removed up to 72h for 
determination of RAD51 protein expression (Suppl. Fig. 1). Treatment with 0.2µg/ml MMS 
was found to induce RAD51 protein expression ~2.5 fold by 24h and ~5 fold by 48h. TK6 
cells were then pre-treated for 24h with 0.2µg/ml MMS to induce RAD51 protein expression 
followed by treatment with AD3-hprtPM or control oligonucleotide (Fig. 3). Treatment with 
oligonucleotide up to 10µM was not found to be excessively cytotoxic (Fig. 3A) and the pre-
treatment of TK6 cells with 0.2µg/ml MMS was not found to be significantly genotoxic 
(comparing Untreated vs.0.2µg/ml MMS treated Background). Interestingly, the biologically 
active ASO, AD3-hprtPM, was found to induce the HPRT mutant frequency in a dose 
dependent manner (Fig. 3B). Treating TK6 cells with 5µM AD3-hprtPM induced the HPRT 
mutant frequency ~1.5 fold above 5µM control oligonucleotide and ~4.4 fold with 10µM 
treatment. Genotoxicity was not observed at the non-targeted TK locus following AD3-
hprtPM treatment suggesting a sequence specific mode of action (Fig. 3C).  
Genotoxicity caused by AD3-hprtPM was proposed to be a result of an overactive HR 
repair pathway initiated by the MMS pre-treatment. This conclusion was supported when 
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AD3-hprtPM failed to induce mutation at the targeted HPRT locus following omission of the 
MMS pre-treatment (Suppl. Fig 2).   
 
Analysis of AD3-hprtPM induced HPRT mutant clones. 
According to the proposed TNE model, mutation within duplex DNA is directed to the site of 
the mismatched base (Aarts et al., 2006, Bonner and Kmiec, 2009, Dekker et al., 2003, 
Morozov and Wawrousek, 2008, Olsen et al., 2009). Thus, to confirm sequence specific 
mutation by AD3-hprtPM, a restriction fragment length polymorphism (RFLP) assay was 
designed. The target region of AD3-hprtPM, within exon 3 of the HPRT locus, was PCR 
amplified to yield a 1Kb fragment. AD3-hprtPM mediated mutation at the mismatched base 
would be expected to result in a G>T transversion causing the loss of a 5’-GATC-3’ Mbo I 
restriction enzyme recognition sequence. PCR fragments containing the mutant sequence 
would be rendered resistant to Mbo I digestion. Those which retained the wild-type sequence 
would yield 2 cleavage products of ~550bp and ~450bp. 
Mbo I digestion of 14 control and 29 AD3-hprtPM induced HPRT mutant clones 
resulted in cleavage of all PCR products into 2 fragments, contradicting the expected 
mechanism of mutagenesis (Suppl. Fig. 3). DNA sequencing of PCR amplified HPRT 
mutant clones (41 AD3-hprtPM induced HPRT mutant clones and 29 control) supported the 
retention of the wild-type 5’-GATC-3’ sequence at position 138 (Fig. 4). However, DNA 
sequencing also revealed a single base deletion (position 171; 34%) adjacent to a single G>A 
transition mutation (position 172; 29%) downstream of the AD3-hprtPM target sequence 
(underlined; position 134-156). These mutations were primarily found in AD3-hprtPM 
induced HPRT mutant clones and not control. The frequency of particular point mutations 
upstream (G>A position 126; 58% control vs. 81% AD3-hprtPM) and downstream (G>A 
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position 158; 19% control vs. 51% AD3-hprtPM) of the AD3-hprtPM target sequence were 
also found to be effected following AD3-hprtPM treatment.  
 
Incorporation of ASO derived nucleotide analogues into a primed DNA template.  
Following reports of serum nucleases capable of degrading phosphorothioate 
oligonucleotides after 1h (Hoke et al., 1991, Morvan et al., 1993), this study has also 
addressed the capability of nucleotide analogues to be incorporated into newly synthesised 
DNA. In the first approach, an in vitro primer extension assay, adapted from Lacenere et al. 
(2006), was engineered to inform the potential of Tfi DNA polymerase to incorporate 
nucleotide analogues commonly used in ASO design. Incorporation of nucleotide analogue 
was informed by extension of primed template by five nucleotides. Using this model, DNA 
polymerase was able to extend the primed template to full length using 0.5µM 
deoxyadenosine triphosphate (dATP), as a control, in a 10 minute reaction (Fig. 5A).  
 Using a phosphorothioate analogue of dATP (dATPαS); where a non-bridging oxygen 
in the α-phosphate moiety is replaced with sulphur (the most common type of chemical 
modification used in ASO design (Buchini and Leumann, 2003)), Tfi DNA polymerase was 
able to fully extend the template using 2µM dATPαS in a 20 minute reaction (Fig. 5B). In 
comparison to the unmodified dATP, this correlates to a relative incorporation efficiency of 
~12%. On the contrary, using a 2’O-methyl-ATP modified analogue (2’OMe-ATP); where 
the 2’ hydroxyl group on the ribose moiety of ATP is replaced with O-methyl to increase 
ASO target binding affinity (Yoo et al., 2004), Tfi polymerase failed to extend the primed 
template in a 60 minute reaction (Fig. 5C).  
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Genotoxicity of phosphorothioate nucleotide analogues.  
 Having shown DNA polymerase was capable of incorporating the non-canonical 
phosphorothioate analogue dATPαS into a primed template in vitro, genotoxicity caused by 
incorporation of this analogue into genomic DNA in vivo was assessed through the integrity 
of the HPRT and TK loci in human TK6 cells. Of important consideration was that 
degradation of oligonucleotides would not yield nucleotides as a triphosphate but rather as 
monophosphates. Thus, to reflect a true biologically relevant event, taking into account the 
prerequisite for phosphorylation of monophosphate nucleotides into triphosphates before 
utilisation by DNA polymerase, TK6 cells were treated with monophosphate 
phosphorothioate nucleotide (dAMPαS). 
 Human TK6 cells were treated for 24h with dAMPαS up to 1mM. As a control, TK6 
cells were also treated with 1mM of the unmodified dAMP nucleotide to allow comparison of 
genotoxicity caused by the single substitution of oxygen for sulphur in the 5’ phosphate 
group.   
 Cytotoxicity following dAMPαS treatment was acceptable up to 0.5mM (30% RTG) 
whilst treatment with the nucleotide control, dAMP, was much less cytotoxic (60% RTG) 
(Fig. 6A).  
 Treatment of TK6 cells with dAMP and dAMPαS failed to induce mutation at the 
HPRT locus (Fig. 6B). In contrast, treatment with dAMPαS resulted in a dose dependent 
increase in TK mutants ~20 fold (0.5mM) and ~96 fold (1mM) above control (Fig. 6C). As 
1mM dAMPαS failed to induce mutation at the HPRT locus (Fig. 6B), a cytotoxicity based 
mechanism of mutation at the TK locus could be excluded. In contrast, 1mM dAMP treatment 
marginally induced the TK mutant frequency (Fig. 6C). Thus, the genotoxicity of 1mM 
dAMPαS was significantly (~56 fold) more potent than the unmodified counterpart. In fact, 
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genotoxicity at either the HPRT or TK loci was no greater than ~3 fold for treatment of TK6 
cells with canonical deoxyadenosine, dAMP or dATP (Suppl. Fig. 4). 
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Discussion 
Data presented in this study suggest that a biologically active ASO, AD3-hprtPM, and its 
phosphorothioate nucleotide analogue degradation product are capable of inducing mutation 
at genomic DNA in human lymphoblastoid TK6 cells. 
Oligonucleotides have been previously reported to be capable of inducing mutation 
within a homologous sequence in duplex DNA, in a process known as TNE, where mutation 
is a result of a mismatched base within the oligonucleotide (Aarts et al., 2006, Bonner and 
Kmiec, 2009, Dekker et al., 2003, Morozov and Wawrousek, 2008, Olsen et al., 2009). An 
important point to consider is that oligonucleotides employed in these studies tend to be 
greater than 45 nucleotides in length. In this study, AD3-hprtPM (23 nucleotides in length) 
was engineered to reflect the length of an ASO therapeutic and chemically modified to 
contain the commonly employed phosphorothioate linkages (Buchini and Leumann, 2003, 
Geary, 2009).  
Although AD3-hprtPM was biologically active as an antisense molecule, mutation at 
the targeted HPRT locus in human lymphoblastoid cells was not observed above the detection 
limit of the assay, unless, RAD51 protein expression was stimulated prior to treatment. In 
that instance, AD3-hprtPM induced locus and sequence specific mutation ~4.4 fold above 
control. Sequencing HPRT mutant clones revealed mutation at the site of the mismatched 
base was absent in all clones. However, amongst other mutations, a single base deletion and 
point mutation adjacent to but downstream of the AD3-hprtPM target sequence was 
predominant in mutant clones derived from AD3-hprtPM treatment and not control.  
We propose that AD3-hprtPM binding to its target sequence on the sense strand (non-
transcribed) is facilitated by the strand pairing properties of RAD51 protein, perhaps during 
DNA replication (Gupta et al., 1997, Kow et al., 2007, Sung and Robberson, 1995). Indeed, 
the ability of RAD51 to pair single stranded DNA with homologous double stranded DNA 
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has been previously reported (Gupta et al., 1997, Sung and Robberson, 1995). Upon strand 
invasion, a “displacement loop” structure is formed which results in the displacement of the 
antisense strand. Following this, the model can be extrapolated from Hanawalt (1994) and 
Wang et al. (1996). The displacement loop structure may result in a physical blockade to a 
progressing replication/transcription fork causing it to revert back to a natural pause site 
generating a reiterative repair patch. Repeated attempts in replication/transcription may result 
in mutation introduced by the natural error frequency of the DNA repair polymerase. It may 
be the bound AD3-hprtPM is removed by the helicase activity associated with a progressing 
fork but repeated cycles of binding, inhibition of replication/transcription and re-iterative 
repair increase the probability of a mutagenic event.  
Alternatively, perhaps through HR repair during S-phase (Johnson and Jasin, 2001, 
Takata et al., 1998), AD3-hprtPM physically incorporates into the genome following RAD51 
mediated strand invasion (Radecke et al., 2006). Once incorporated, AD3-hprtPM with the 
mismatched base and the non-canonical phosphorothioate linkages at either end may cause 
replication fork arrest. The sulphur within the phosphodiester backbone is likely to be 
recognised as a lesion by the nucleotide excision repair (NER) pathway ultimately resulting 
in the excision of an encompassing fragment of 27-29nt in length (Huang et al., 1992, 
Svoboda et al., 1993). In support of this, the introduction of phosphorothioate bonds in a 
DNA double helix has been reported to cause structural alterations (Kanaori et al., 1999). 
This mechanism may also explain why the mismatched base from AD3-hprtPM treatment 
was not observed in HPRT mutant clones but was observed in previous studies using 
oligonucleotides that are far greater in length than the NER repair pathway is able to cleave. 
In this study, human TK6 cells were transfected with oligonucleotide for 4h, which 
was then removed by washing. Exposure of cells to oligonucleotide for longer periods of time 
may increase the probability for ASO hybridisation to genomic DNA and mutation. For 
Page 18 of 38Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 19 
 
example, in a Phase I/II clinical trial using a 2’OMe/phosphorothioate ASO (PRO051, 
Prosensa Therapetucis), plasma half-life of oligonucleotide was between 19 and 56 days 
(Goemans et al., 2011). Additionally, subcutaneous injection of a phosphorothioate ASO has 
been shown to rapidly distribute to the liver in mice and remain there with a half-life up to 19 
days (Yu et al., 2001). In fact, ASO elimination from the liver was reduced with increasing 
ASO dose. Thus, accumulation and constant exposure of cells to ASO may increase the 
probability of ASO hybridisation to genomic DNA and subsequent mutation; repeated cycles 
of ASO binding may further increase the likelihood of mutation. This hypothesis is supported 
from a study by Leonetti et al. (1991) and Chin et al. (1990) where micro-injected 
oligonucleotides were shown to rapidly accumulate in the cell nucleus and not the cytoplasm. 
ASO binding to genomic DNA is even more likely when ASO accumulate in the cell nucleus.  
These data suggest that a mismatched base within an ASO may not be a pre-requisite 
for mutation at its homologous sequence in genomic DNA providing RAD51 protein 
expression is sufficient to mediate strand invasion of duplex DNA. The dependence of AD3-
hprtPM mediated mutagenesis on RAD51 protein induction is clinically relevant to patients 
with p53 mutant tumors that are often found to have elevated RAD51 protein expression; it 
has been proposed that RAD51 overexpression may contribute to drug resistance and 
genomic instability (Klein, 2008). Furthermore, the majority of ASO currently in clinical 
trials are for cancer therapy and p53 is inactivated in half of human cancers (Soussi and 
Lozano, 2005). Since p53 negatively regulates RAD51 gene expression these patients may 
also present with elevated RAD51 protein expression (Arias-Lopez et al., 2006, Hannay et 
al., 2007). For example, the extent of RAD51 protein expression in invasive ductal breast 
cancer correlated with the histological grading of tumors and RAD51 is reportedly induced 2-
7 fold in several cancer cell lines similar to that reported here (Maacke et al., 2000, 
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Raderschall et al., 2002). However, how our in vitro genotoxicity data translates to an in vivo 
system is unknown and warrants further investigation. 
ASO that are degraded can result in the release of non-canonical nucleotides, which 
may enter endogenous nucleotide pools and incorporate into newly synthesised DNA during 
replication. Data presented here suggest that a DNA polymerase can utilise a 
phosphorothioate nucleotide analogue (dATPαS), albeit with reduced efficiency (~8 fold 
relative to unmodified counterpart), but failed to incorporate a 2’Omethyl RNA based 
nucleotide (2’Ome-ATP) into a primed template. It would appear that incorporation of 
nucleotide analogues may entirely depend on the nature of the chemical modification. 
Treating human lymphoblastoid cells with the phosphorothioate analogue dAMPαS 
resulted in significant mutation with an apparent thresholded effect. Remarkably, mutation at 
the genomic TK locus was up to 2 orders of magnitude above control, yet mutation at the 
HPRT locus was not observed. Previous studies suggest that a large proportion of mutations 
at the HPRT locus can be deleterious to the cell whilst the TK locus is a more robust reporter 
capable of detecting point mutations and even inter-gene deletions (Doak et al., 2007, 
McGregor et al., 1996) and we suggest that this may be the case here. 
Human TK6 cells were treated with the monophosphate analogue dAMPαS and so for 
incorporation into genomic DNA (i) the concentration of dATPαS must exceed a threshold 
for insertion of analogue rather than endogenous dATP and (ii) dAMPαS must first become a 
substrate for various kinases to convert the monophosphate into a triphosphate for utilisation 
by DNA polymerase. In essence, both these limitations would contribute to a genotoxic 
threshold as observed in the data presented here. Considering this thresholded effect at the TK 
locus, we suggest the mechanism of mutation by dAMPαS may be in accordance with the 
next nucleotide effect model (Phear et al., 1987). The speed at which DNA polymerase 
extends an elongating strand (5’ to 3’) is governed by the availability of the next (3’) 
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nucleotide in sequence. If a misinserted nucleotide is followed 3’ by a highly abundant 
nucleotide, polymerisation of this next nucleotide is favoured rather than the excision of the 
incorrect one by the 3’ to 5’ exonuclease activity associated to DNA polymerase (Fersht, 
1979). However, in this case, the insertion of the phosphorothioate analogue, dATPαS, would 
render the bond nuclease resistant thereby  locking the error into the sequence.  
It is particularly important to note that although 0.5mM dAMPαS treatment was 
mutagenic in an in vitro system, the in vivo relevance is unknown; phosphorothioate 
oligonucleotides are thought to slowly degrade over time but data is lacking to inform in vivo 
intracellular concentrations of ASO derived nucleotide analogues.  Nevertheless our findings 
raise the question as to whether ASO modalities and their respective degradation products 
can contribute to genomic instability.  
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Supplementary Data 
Supplementary Figures 1-4 can be found online. 
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Figure legends 
 
Figure 1. Oligonucleotide sequences. The target sequence in exon 3 of the HPRT locus is 
shown as a duplex and underlined. AD3-hprtPM antisense oligonucleotide is designed to bind 
complementary to the non-transcribed strand, except a single mismatched base (bold 
lowercase). Control oligonucleotide has no sequence similarity to the HPRT locus. 
 
Figure 2. Antisense activity of AD3-hprtPM oligonucleotide. TK6 cells were treated with 2 
µM, 5 µM or 10 µM AD3-hprtPM or control oligonucleotide. ADAMTS3 protein expression 
at 24 h (A), 48 h (B) and 72 h (C) was determined by immunoblot. ADAMTS3 expression 
was quantified by densitometry and corrected for GAPDH loading control. ADAMTS3 
protein expression following AD3-hprtPM  treatment was normalised to control 
oligonucleotide treatment at the respective time and dose (D). Data represent mean ± SD of 
three independent treatments. ADAMTS3 protein expression from AD3-hprtPM treatment is 
compared to control oligonucleotide at the same dose and time using a two-way student’s t-
test. * p<0.05. 
 
Figure 3. Genotoxicity of AD3-hprtPM in a HR repair induced system. Human TK6 cells 
were pre-treated with 0.2 µg/ml MMS for 24 h to induce the HR repair pathway. The 
Untreated group measures the cytotoxic/genotoxic effect of the MMS pre-treatment. The 
spontaneous mutant frequency following MMS pre-treatment was determined as Background. 
EMS (5µg/ml) was used as a positive genotoxin. Cytotoxicity below the minimum accepted 
20% RTG is not evident following treatment of TK6 cells with 2 µM, 5 µM or 10 µM 
oligonucleotide (A). AD3-hprtPM induced a dose dependent increase in HPRT mutants 
relative to control oligonucleotide (B). AD3-hprtPM oligonucleotide failed to induce 
mutation at the non-targeted TK locus (C). Data represent mean ± SD of three independent 
treatments. * p<0.05 using two-way students t-test. 
 
Figure 4. Distribution of AD3-hprtPM mediated mutation in exon 3 of the HPRT locus. 
Sequences are numbered from the first base of exon 3 (1 to 164). The AD3-hprtPM target 
sequence is underlined from position 134-156. * above guanine (position 138) indicates the 
site of the mismatched base in AD3-hprtPM where G>T transversion mutation was predicted. 
Numbers and letters within a circle represent the frequency (%) and type of mutation from 41 
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AD3-hprtPM induced HPRT mutant clones whereas those in a square are from 29 control 
oligonucleotide induced HPRT mutant clones. + indicates an insertion and ∆ indicates a 
deletion.    
 
Figure 5. Efficiency of nucleotide analogue incorporation into a primed DNA template. Two 
complimentary oligonucleotide strands (25 nt and 30 nt) were annealed together to produce 
an overhang of five thymidine nucleotides. The ability to extend the short strand by five 
nucleotides is used as the marker for incorporation of nucleotide. The values above each lane 
are dose of nucleotide analogue (µM). Full extension of the primed template was found to 
occur in a 10 minute reaction with 0.5 µM dATP (A). Incorporation of the phosphorothioate 
nucleotide analogue, dATPαS, was in a 20 minute reaction at 2 µM (B). Here, dATP (5 µM) 
was used as a positive control (lane C) to reference an extended template. DNA polymerase 
failed to incorporate the nucleotide analogue, 2’Omethyl-ATP, into the primed template in a 
60 minute reaction (C). 
 
Figure 6. Genotoxicity of dAMPαS nucleotide analogue incorporation into genomic DNA. 
Human TK6 cells were treated with nucleotide analogue dAMPαS from 20 µM up to 1mM 
for 24 h. As a nucleotide control, TK6 cells were also treated with 1 mM dAMP. The zero 
dose is the negative control (solvent). EMS (5 µg/ml) was used as a positive genotoxin. For 
mutation assays, RTG above 20% are considered acceptable; only treatment with 1 mM 
dAMPαS (10% RTG) was below this threshold (A). Mutation at the HPRT locus was not 
observed (B). However, treatment with dAMPαS resulted in a dose dependent increase in TK 
mutants up to 96 fold above control (C). The unmodified nucleotide, dAMP (1mM), induced 
the TK mutant frequency ~1.7 fold (C). * p<0.05; ** p< 0.01; *** p<0.001 using one-way 
ANOVA with Dunnett’s post-hoc test compared to control. 
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